Unveiling therapeutic potentials and exploring maternal‐fetal health benefits of metformin in pregnancy: A scoping review
International Journal of Gynecology & Obstetrics · 2024
DOI: 10.1002/ijgo.15728 ↗Kurz gefasst
Scoping Review in der Zeitschrift International Journal of Gynecology & Obstetrics, 2024. Verfasst von Daniele Neola und 11 weiteren Autor:innen. Beteiligte Einrichtung: Department of Neuroscience, Reproductive Sciences and Dentistry, School of Medicine, University of Naples Federico II, Naples, Italy. Hauptthemen laut MEDLINE: Metformin, Hypoglycemic Agents, Diabetes, Gestational, Diabetes Mellitus, Type 2. Die Arbeit wurde bisher 2-mal zitiert (Crossref) und nennt 26 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY-NC-ND 4.0).
Abstract (Originalsprache)
This scoping review synthesizes evidence on metformin's use during pregnancy, encompassing diverse conditions like gestational diabetes, type 1 and type 2 diabetes, polycystic ovary syndrome (PCOS), and obesity. Metformin demonstrates comparable efficacy to insulin in gestational diabetes, positive outcomes in type 2 diabetes pregnancies, and potential benefits in reducing complications. The review highlights nuances in its effects across conditions, indicating advantages such as reduced risk of macrosomia and cesarean section in gestational diabetes. However, its prophylactic role in preventing gestational diabetes and associated complications remains inconclusive. In obese pregnant women, mixed results are observed, with potential benefits in reducing pre‐eclampsia risk. Metformin shows promise in preventing preterm birth and late miscarriage in PCOS pregnancies. Categorizing patient subgroups is crucial for identifying advantages, especially in gestational diabetes and type 2 diabetes. Challenges arise from study heterogeneity, necessitating standardized indications for dosage, timing, and postpartum follow ups. Efforts to identify patient characteristics influencing metformin efficacy are crucial for tailored therapy. Although metformin emerges as a viable option in complicated pregnancies, comprehensive research, standardized protocols, and subgroup identification efforts will enhance clinical utility, ensuring evidence‐based therapies and optimal maternal and fetal outcomes. Bridging existing knowledge gaps remains imperative for advancing metformin's role in pregnancy management.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- Department of Neuroscience, Reproductive Sciences and Dentistry, School of Medicine, University of Naples Federico II, Naples, Italy.
- Obstetrics and Gynecology Unit, Sant'Anna e San Sebastiano Hospital, Caserta, Italy.
- Department of Public Health, University of Naples Federico II, Naples, Italy.
ORCID-Profile: Daniele Neola
Zitieren
APA
Neola, D., Angelino, A., Sirico, A., Murolo, C., Bartolini, G., Vigilante, L., Raffone, A., Carbone, L., Sarno, L., Saccone, G., Guida, M., & Maruotti, G. M. (2024). Unveiling therapeutic potentials and exploring maternal‐fetal health benefits of metformin in pregnancy: A scoping review. International Journal of Gynecology & Obstetrics. https://doi.org/10.1002/ijgo.15728
Vancouver
Neola D, Angelino A, Sirico A, Murolo C, Bartolini G, Vigilante L, et al. Unveiling therapeutic potentials and exploring maternal‐fetal health benefits of metformin in pregnancy: A scoping review. International Journal of Gynecology & Obstetrics. 2024. doi:10.1002/ijgo.15728
BibTeX
@article{Neola2024,
author = {Neola, Daniele and Angelino, Antonio and Sirico, Angelo and Murolo, Chiara and Bartolini, Giorgia and Vigilante, Luigi and Raffone, Antonio and Carbone, Luigi and Sarno, Laura and Saccone, Gabriele and Guida, Maurizio and Maruotti, Giuseppe Maria},
title = {Unveiling therapeutic potentials and exploring maternal‐fetal health benefits of metformin in pregnancy: A scoping review},
journal = {International Journal of Gynecology & Obstetrics},
year = {2024},
doi = {10.1002/ijgo.15728}
}
EUVIMED